Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry comprises the collective surface molecules exposed to the host immune system or environment by the pathogens Salmonella enterica and Mycoplasma hyopneumoniae, including a wide variety of surface proteins (e.g., adhesins, lipoproteins, proteases), membrane proteins, and polysaccharides (e.g., LPS, capsules). Each surface molecule often possesses distinct structural, immunomodulatory, and adhesive functions, and many are primary targets for host immunity, diagnostic assays, drug development, or vaccine design. The surfaceome of both bacteria is exceptionally diverse, shaped by post-translational modifications, proteolytic events, and genetic variability, making it a rich source of potential targets and simultaneously complicating efforts for therapeutic targeting or biomarker selection.
Inhibition of adhesion; Induction of bactericidal immunity; Direct antibacterial activity; Blockade of virulence mechanisms
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Broad array of surface proteins, membrane proteins, polysaccharides, and other exposed antigens on Salmonella enterica and Mycoplasma hyopneumoniae.